Clinical Trial: A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
Study Status: Completed
Recruit Status: RECRUITING
Condition: Neuroendocrine Tumors
Study Type: INTERVENTIONAL
Official Title: A Phase 1, First-in-human Clinical Trial of [212Pb] VMT-alpha-NET Using a Forward Dosimetric Planning Technique to Treat Refractory or Relapsed Neuroendocrine Tumors
Brief Summary:
This is a safety study to determine the recommended dose to test in clinical trials.The study involves two treatments with 212Pb (212-lead) VMT-?-NET.This is a safety study only; it will most likely not provide therapeutic benefit.
Read more